Evidence map›Paper›PMID 40765823›Full record

ArticleInternational journal of biological sciences2025

Tissue Factor Pathway Inhibitor 2 Enhances Hepatocellular Carcinoma Chemosensitivity by Activating CCAR2-GADD45A-Mediated DNA Damage Repair.

Hongzhong Zhou, Liwen Zhu, Yajun Zhang, Lichan Chen, Dong-Mei Gou, Haohua Zhang, Rongmao Hua, Jianning Song, Chuanghua Qiu, Fu-Wen Yao and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hongzhong ZhouDepartment of Laboratory Medicine, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, Shenzhen University, China.
Liwen ZhuDepartment of Laboratory Medicine, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, Shenzhen University, China.
Yajun ZhangGuangzhou University of Chinese Medicine, Guangzhou, China.
Lichan ChenShenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China.
Dong-Mei GouShenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China.
Haohua ZhangDepartment of Laboratory Medicine, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, Shenzhen University, China.
Rongmao HuaDepartment of Laboratory Medicine, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, Shenzhen University, China.
Jianning SongDepartment of Laboratory Medicine, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, Shenzhen University, China.
Chuanghua QiuDepartment of Laboratory Medicine, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, Shenzhen University, China.
Fu-Wen YaoLeland Stanford Junior University, USA.
Xiafei WeiShenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China.
Dayong GuDepartment of Laboratory Medicine, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, Shenzhen University, China.
Yong XuShenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy resistance presents a major challenge in the treatment of hepatocellular carcinoma (HCC), with the underlying molecular mechanisms largely unknown. This study aimed to investigate the role of tissue factor pathway inhibitor 2 (TFPI2) in modulating HCC chemosensitivity. We explored the impact of TFPI2 on sorafenib sensitivity in patient-derived organoids and mouse models using immunofluorescence analysis, chromatin immunoprecipitation, and RNA immunoprecipitation. We observed the downregulation of TFPI2 in HCC, and its deletion in mice (TFPI2

Indexed as

Carcinoma, HepatocellularCell Cycle ProteinsGlycoproteinsLiver NeoplasmsNuclear ProteinsAnimalsCell Line, TumorDNA DamageDNA RepairGADD45 ProteinsHumansMaleMiceSorafenibCell Cycle ProteinsGADD45A protein, humanGADD45 ProteinsGlycoproteinsNuclear ProteinsSorafenibtissue-factor-pathway inhibitor 2chemoresistancehepatocellular carcinomamRNA stabilityorganoidTFPI2

Identifiers

PMID40765823
PMCPMC12320495

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.